Glycoproteomic Innovator Grant: Run up to 200 samples for biomarker discovery with GlycoVision. Apply now until Aug 16, 2024!
hero guy

Now we can see the full spectrum of our health

We’ve developed the GlycoVision™ platform to exponentially improve the speed, scope, and scale of glycoproteomics, thereby enabling new insights into biomarker discovery, disease detection and progression, therapeutic response, and monitoring.

A new era of precision medicine is here.

Discover GlycoVision

High-resolution glycoproteomics

At InterVenn Biosciences, we’ve leveraged our proprietary AI-driven platform to unlock the glycoproteome with unparalleled detail, allowing us to explore this untapped layer of biology on a clinically meaningful scale for the first time in history.

Glycosylation of proteins controls the activation state of immune cells and can distinguish specific physiological states. By exploring how proteins are glycosylated and how these modifications affect protein function, we can uncover invaluable insights into the molecular mechanisms underlying health and disease.

Learn About Glycoproteomics

Early Detection Matters

Once available, GlycoKnow™ Colon will be a blood-based laboratory-developed test that measures the body’s early response to colorectal cancer progression. Powered by Glycovision, GlycoKnow Colon assesses the presence of adenomas with high-grade dysplasia or colorectal cancer, empowering healthcare professionals to take action before the onset of disease, when intervention is most optimal.

Explore GlycoKnow Colon

Who We Are

We are a life sciences company founded on the belief that no one should ever be blindsided by disease. We aim to expand the -omics universe by harnessing the power of the glycoproteome - ushering in a new era of personalized, predictive, and preventive care.

About Us

Clinical Evidence

Decoding the glycoproteome: a new frontier for biomarker discovery in cancer

Journal of Hematology & Oncology | March 22, 2024

Early Detection of Advanced Adenomas and Colorectal Carcinoma by Serum Glycoproteome Profiling

Gastroenterology | September 25, 2023

Variable PD-1 glycosylation modulates the activity of immune checkpoint inhibitors

Frontier in Immunology | June 13, 2023

Get in touch